EWA vs XBI
iShares MSCI Australia ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.50% for EWA.
- • EWA pays a higher dividend yield (2.88%).
Side-by-side metrics
| Metric | EWA | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.50% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.88% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $1.25B | $10.92B |
YTD return | 14.89% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.94 | 1.01 |
P/E ratio | 20.32 | — |
Last price | $29.40 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
EWA top holdings
| BHP.AX | BHP Group Ltd | 14.33% |
| CBA.AX | Commonwealth Bank of Australia | 13.67% |
| NAB.AX | National Australia Bank Ltd | 6.34% |
| WBC.AX | Westpac Banking Corp | 6.17% |
| ANZ.AX | ANZ Group Holdings Ltd | 6.03% |
| CSL.AX | CSL Ltd | 4.71% |
| MQG.AX | Macquarie Group Ltd | 4.51% |
| WES.AX | Wesfarmers Ltd | 4.27% |
| WDS.AX | Woodside Energy Group Ltd | 3.10% |
| RIO.AX | Rio Tinto Ltd | 2.68% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About EWA
EWA (iShares MSCI Australia ETF) is Australian large and mid-cap equities. Managed by iShares, the fund carries $1.2B in assets under management, an expense ratio of 0.50%, a dividend yield of 2.88%. Its largest holding is BHP Group Ltd (BHP.AX), which represents 14.3% of the portfolio. Real Estate is the fund's largest sector exposure at 4.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.